The Vox Markets Podcast
/
Jeremy Skillington of Poolbeg Pharma discusses their exclusive in-licence of RNA-based immunotherapy asset
Our original embed player - you can use this to maintain continuity with any other episodes you've already embedded. Otherwise we'd suggest
upgrading to our new player.